Telephone
61.8.6280.0050
Address
Suite 2, Level 2 66 Kings Park Road West Perth, Western Australia (WA) 6005
Description
Little Green Pharma Ltd. produces medicinal cannabis products for sale to Australian patients. Its medicines are cultivated, without pesticides, in a hydroponic facility. The company was founded in 2017 and is headquartered in West Perth, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.12 - 0.28
Trade Value (12mth)
AU$10,933.00
1 week
4.17%
1 month
-10.71%
YTD
-28.57%
1 year
-32.43%
All time high
1.017
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
299m
HALO Sector
Industrials
Next Company Report Date
29-May-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
Quarterly Activities Report & Appendix 4C
×
Quarterly Activities Report & Appendix 4C |
31 October 22 |
Trading Halt
×
Trading Halt |
31 October 22 |
Quarterly Activities Report & Appendix 4C
×
Quarterly Activities Report & Appendix 4C |
31 May 23 |
Preliminary Final Report
×
Preliminary Final Report |
31 May 22 |
Preliminary Final Report
×
Preliminary Final Report |
31 March 23 |
Application for quotation of securities - LGP
×
Application for quotation of securities - LGP |
31 March 23 |
Cleansing notice
×
Cleansing notice |
31 March 23 |
Change in substantial holding - Tiga Trading Pty Ltd
×
Change in substantial holding - Tiga Trading Pty Ltd |
31 July 23 |
Letter to Shareholders regarding Annual General Meeting
×
Letter to Shareholders regarding Annual General Meeting |
31 January 23 |
Results of Meeting
×
Results of Meeting |
31 August 20 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 November 23 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
30 November 23 |
Half Yearly Financial Presentation
×
Half Yearly Financial Presentation |
30 November 23 |
CEO Update on Financial Results
×
CEO Update on Financial Results |
30 November 22 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
30 November 22 |
Ethics approval for CBD Phase III clinical trial
×
Ethics approval for CBD Phase III clinical trial |
30 June 23 |
Corporate Governance Statement and Appendix 4G
×
Corporate Governance Statement and Appendix 4G |
30 June 23 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 December 22 |
Change in substantial holding
×
Change in substantial holding |
30 August 23 |
Annual General Meeting Results Additional Information
×
Annual General Meeting Results Additional Information |
30 August 22 |
Results of Meeting
×
Results of Meeting |
30 April 20 |
Investor Presentation
×
Investor Presentation |
29 September 21 |
Annual Report to shareholders
×
Annual Report to shareholders |
29 July 22 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
29 July 22 |
Letter to Shareholders regarding Annual General Meeting
×
Letter to Shareholders regarding Annual General Meeting |
29 December 22 |
Notice of General Meeting
×
Notice of General Meeting |
29 December 22 |
Letter to Shareholders regarding General Meeting
×
Letter to Shareholders regarding General Meeting |
29 August 23 |
AGM Presentation and Company Update
×
AGM Presentation and Company Update |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.